cps3 Antibody

Definition and Biological Context

The cps3 Antibody specifically binds to the type 3 capsular polysaccharide, a key virulence factor of encapsulated bacteria. CPS protects pathogens from phagocytosis, making anti-CPS antibodies essential for host defense . Serotype 3 is notable for its unique CPS synthesis pathway, where polysaccharides are not covalently linked to peptidoglycan, enabling their release during bacterial growth .

Key Findings

• Opsonizing IgG Production: Immunization with purified serotype 3 CPS adjuvanted with TiterMax Gold in mice induced opsonizing IgG responses, unlike other serotypes (e.g., 7, 8, or 9) .

• Complement Activation: Anti-cps3 antibodies enhance classical complement pathway activation, increasing C3, C1q, and C4 deposition on bacterial surfaces .

• Primary vs. Secondary Responses: Primary infection with S. suis serotype 3 elicits IgM and IgG responses, but only IgM is boosted during secondary infection .

Immune Adherence and Phagocytosis

• Anti-cps3 antibodies facilitate immune adherence by promoting interactions between erythrocytes and macrophages via CR3 and Fcγ receptors .

• Complement-Mediated Clearance:

  Mechanism	Effect	Reference
  C3 Deposition	Enhanced via classical pathway
  Opsonophagocytic Killing	Reduced by free CPS3 in vitro and in vivo
  Erythrocyte Transfer	Increased bacterial transfer to macrophages

CPS Release and Antibody Interference

Serotype 3 releases CPS during growth, which neutralizes antibody-mediated protection:

• In Mice: 0.03 μg of free CPS3 abolished protection against 10⁴ CFU of S. pneumoniae, whereas 100× more CPS4 was required for similar inhibition .

• Clinical Relevance: Higher antibody titers may be needed in humans for protection against serotype 3 due to CPS release .

Comparative CPS Release

Next-Generation Vaccines

• MAPS Vaccine: Combines CPS3 with the protein antigen SPP2, showing synergistic protection in murine models. Passive immunization with MAPS-generated antibodies protected against invasive disease, unlike PCV13 .

• Adjuvant Optimization: TiterMax Gold improved IgG responses to CPS3 compared to alum or Freund’s adjuvant .

Key Studies

1. CPS3-Induced Antibody Dysfunction (2015–2016): Demonstrated that CPS3 release inhibits opsonophagocytic killing and passive protection in mice .

2. Complement and Fc Receptor Synergy (2008–2023): Highlighted the role of CR3 and FcγRIII/II in macrophage uptake of CPS3-opsonized bacteria .

3. Hexameric Antibody Engineering (2023): Modified anti-CPS antibodies (e.g., E430G mutation) improved complement activation and neutrophil phagocytosis .